Lantheus doses first patient in SPARROW Phase 2/3 prostate cancer imaging trial for LNTH-2401
Bitget2026/09/28 12:04- Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational study of LNTH-2401 PET imaging in prostate cancer.
- No clinical results were presented; the trial is designed to generate data for a future diagnostic performance readout.
- The study aims to show LNTH-2401 can help detect and characterize prostate cancer using a GRPR-targeted approach complementary to PSMA imaging.
- Phase 3 is expected to enroll about 400 participants, positioning the program as a potential pipeline expansion in prostate cancer imaging.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
